-
-
FILE - In this Friday, July 13, 2012 file photo, Merck CEO Kenneth Frazier speaks at a news conference after a meeting at Penn State University's Worthington Scranton campus in Dunmore, Pa. Frazier is convinced nearly everyone, from patients to long-term investors, wants the world's third-largest drugmaker to take big risks. One of Merck's biggest gambles is the tens of millions it's pouring into an experimental treatment for a new type of Alzheimer's drug. (AP Photo/Matt Rourke, File)
-
Dr. Mark Molitch of Northwestern University, who helped write medical standards meant to limit HGH treatment to legitimate patients, holds an injector pen that contains approximately a weeks worth of doses for a patient in need of the drug at his clinic Thursday, Dec. 20, 2012, in Chicago. An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies. (AP Photo/M. Spencer Green)
-
This photo shows an injector pen that contains approximately a weeks worth of HGH doses for a patient in need of the drug at the clinic of Dr. Mark Molitch of Northwestern University, who helped write medical standards meant to limit HGH treatment to patients in need of the drug Thursday, Dec. 20, 2012, in Chicago. An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies. (AP Photo/M. Spencer Green)
-
This image made available by Atria Books shows the cover of Dr. Jeffry Life's 2011 book "The Life Plan." Life used testosterone and human growth hormone in his own bodybuilding regimen. (AP Photo/Atria Books, Terry Goodlad)
-
In this Tuesday, June 28, 2011 photo, agents with the Drug Enforcement Administration stand outside the Treasure Coast Pharmacy in Jensen Beach after a raid. shortly before it opened Tuesday morning as part of an ongoing investigation. DEA, the Florida Department of Health, Florida State Troopers, Martin County Sheriff's deputies and Boca Raton and Margate police participated in the investigation. (AP Photo/TCPalm.com, Alex Boerner) MANDATORY CREDIT: TCPALM.COM, ALEX BOERNER
Acadia climbs on data from psychosis drug study
NEW YORK (
AP) — Shares of
Acadia Pharmaceuticals Inc. climbed to a multiyear high on Thursday after the company reported new data from a study of its drug
pimavanserin, which is designed to treat psychosis in patients with Parkinson's disease.
THE SPARK: The San Diego company said the drug met a series of secondary goals in the clinical trial. According to a scale that measures patients' improvement during treatment, about twice as many patients who took pimavanserin were rated "very much improved" or "much improved" compared to patients who took a placebo. Patients who took the drug also improved based on a clinical measurement called the Scale for the Assessment of Positive Symptoms, or SAPS, and on a simpler version of SAPS Acadia developed.
Acadia said patients treated with pimavanserin were less likely to suffer hallucinations and delusions.
THE BIG PICTURE: In November Acadia said pimavanserin had met its main goal in the trial, reducing psychosis as measured by one of the disease scales. It also said pimavanserin did not affect patients' motor control, while patients who took the drug slept better at night, were more awake during the day, and were less of a burden to caregivers.
According to the company, up to 60 percent of Americans with Parkinson's disease develop psychosis and there is no approved therapy to treat the condition. The company said anti-psychotic drugs are sometimes used to treat the psychosis, but those drugs can increase the risk of death and can cause side effects like the loss of motor control.
Pimavanserin is Acadia's most advanced experimental drug. The company does not have any approved products.
THE ANALYSIS: Jefferies & Co. analyst Thomas Wei said he still expects pimavanserin to be approved, and said it helps that patients improved according to the full SAPS scale along with its streamlined version of the scale.
Wood kept a "Buy" rating on Acadia shares with a price target of $13.
SHARE ACTION: Acadia shares rose 25 percent, or $1.67, to $8.32 in morning trading. The stock is now trading at its highest prices since June 2008. The shares closed at $2.30 before Acadia reported the initial results from the trial.
Tags:
parkinson, jefferies, acadia, acadia pharmaceuticals inc., pimavanserin, patients, health, thursday, better, series, share action, price target, spark, scale, percent, trial, company, big picture, treatment, schizophrenia, morning trading, new york, burden, drug, pharmacology, anti-psychotic drugs, delusions, antipsychotic, assessment, hallucinations, secondary goals, clinical trial, main goal, highest prices, new data, initial results, san diego company, placebo, experimental drug, dopamine, psychosis, analyst thomas wei, streamlined version, acadia shares, drug pimavanserin, psychosis drug study, motor control, disease develop psychosis, approved therapy, saps acadia, multiyear high, saps scale, positive symptoms, simpler version, clinical measurement, disease scales
Print Page
